Source:http://linkedlifedata.com/resource/pubmed/id/16417820
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2006-1-18
|
| pubmed:abstractText |
The modest effectiveness of disease modifying therapies (DMTs) in MS has been amply illustrated by a series of pivotal trials, albeit short term in the context of a life-long disease. Most neurologists and people with MS welcome the opportunity to affect the course of this disorder. However, the individual with MS might not be fully aware of the importance of continuing treatment with these drugs in the absence of feeling better (and often feeling worse) while taking therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1352-8963
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
73
|
| pubmed:meshHeading | |
| pubmed:year |
2005
|
| pubmed:articleTitle |
Treatment adherence: what is the best that can be achieved?
|
| pubmed:publicationType |
Editorial
|